期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ACE抑制剂和血管紧张素Ⅱ受体阻断剂在当前高血压治疗中的地位 被引量：4

暂未订购
导出
摘要 高血压对老年人和中年人来说均为心血管病残和病死的主要危险因素。六类抗高血压药物被列为临床实践中的一线用药。其中血管紧张素转化酶(ACE)抑制剂和血管紧张素II受体拮阻断通过阻断肾素-血管紧张素-醛固酮系统而在当前抗高血压治疗中起着重要的作用。本文综述新近公布的多项评价ACE抑制剂和血管紧张素II受体阻断剂对高血压患者临床转归影响的临床研究,认为它们不仅能有效降低血压,在减少各种心血管事件等临床终点方面更具优越性。
作者 李勇 范维琥
机构地区 上海复旦大学附属华山医院心内科
出处 《世界临床药物》 CAS 2003年第5期270-275,284,共7页 World Clinical Drug
关键词 高血压 药物治疗 ACE抑制剂 血管紧张素Ⅱ受体阻断剂 临床研究
分类号 R544.1 [医药卫生—心血管疾病] R972.4 [医药卫生—药品]
  • 相关文献

参考文献21

  • 1Hansson L;Lindholm LH;Niskanen L.Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP)randomized trial,1999.
  • 2Gress TW;Nieto F J;Shahar E.Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus[J],2000(13).
  • 3Anon.The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure[J],1997.
  • 4Hansson L;Hedner T;Lund-Johansen P.Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study[J],2000(9227).
  • 5Anon.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic[J],2002.
  • 6Dahlof B;Devereux R;Kjeldsen S.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE): a randomized trial against atenolol[J],2002(9311).
  • 7Brown M J;Palmer CR;Castaigne A.Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)[J],2000(9227).
  • 8Anon.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack,2001(9287).
  • 9Agodoa LY;Appel L;Bakris GL.Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial,2001.
  • 10Anon.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions,1992(10).

二级参考文献35

  • 1邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量：1428
  • 2唐丽霞.三种长效降压药物治疗方案的最小成本分析[J].药物流行病学杂志,2006,15(4):244-245. 被引量：5
  • 3覃韦苇,田媛,张尊建,许风国,薛志军,陈沄.赖诺普利片在健康志愿者体内的生物等效性评价[J].中国新药与临床杂志,2006,25(12):885-889. 被引量：5
  • 4张毕奎,陈本美,原海燕,朱运贵,冯胜,梁武,马宁,李焕德.人血浆中赖诺普利的液相色谱-质谱法测定及生物等效性研究[J].中国新药与临床杂志,2007,26(6):436-439. 被引量：4
  • 5[3]Pylypchuk GB. ACE inhibitor-versus angiotensin Ⅱ blockerinduced cough and angiodema[J]. Ann Pharmacother, 1998.32(10): 1 060.
  • 6[5]Mimran A,Ruilope L,Kerwin L, et al. A randomized,doubleblind comparison of the angiotensin receptor Ⅱ antagonist,irbesartan,with the full dose rang of enalpril for the treatment of mild - to - moderate hypertension [J] . J Hum Hypertens , 1998,12(3) :203.
  • 7[6]Oparil S.Newly emerging pharmacologic differences in angiotensinⅡ receptor blockers[J]. Am J Hypertens, 2000,13( 1 Pt2): 18S.
  • 8Hu K, Gaudron P, Anders H J, et al. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction:role of bradykinin. Cardiovascular Res, 1998,39(1):401
  • 9Gallagher A M, Yu H, Printz M P. Bradykinininduced reduction in collagen gene expression involve prostacyclin. Hypertension,1998,32(2) :84
  • 10Packer M, Plloe-wilso p, Armstrong P, et al. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure. Eur Heart J,1998,19 SuppI:142

共引文献45

同被引文献40

  • 1邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量：1428
  • 2唐丽霞.三种长效降压药物治疗方案的最小成本分析[J].药物流行病学杂志,2006,15(4):244-245. 被引量：5
  • 3覃韦苇,田媛,张尊建,许风国,薛志军,陈沄.赖诺普利片在健康志愿者体内的生物等效性评价[J].中国新药与临床杂志,2006,25(12):885-889. 被引量：5
  • 4张毕奎,陈本美,原海燕,朱运贵,冯胜,梁武,马宁,李焕德.人血浆中赖诺普利的液相色谱-质谱法测定及生物等效性研究[J].中国新药与临床杂志,2007,26(6):436-439. 被引量：4
  • 5[3]Pylypchuk GB. ACE inhibitor-versus angiotensin Ⅱ blockerinduced cough and angiodema[J]. Ann Pharmacother, 1998.32(10): 1 060.
  • 6[5]Mimran A,Ruilope L,Kerwin L, et al. A randomized,doubleblind comparison of the angiotensin receptor Ⅱ antagonist,irbesartan,with the full dose rang of enalpril for the treatment of mild - to - moderate hypertension [J] . J Hum Hypertens , 1998,12(3) :203.
  • 7[6]Oparil S.Newly emerging pharmacologic differences in angiotensinⅡ receptor blockers[J]. Am J Hypertens, 2000,13( 1 Pt2): 18S.
  • 8Ruggenenti P;Mise N;Pisoni R.Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies[J],2003(04).
  • 9Mogensen CE;Neldam S;Tikkanen I.Randomised controlled trial of dual btockade of renin-angiotensin system in patients with hypertensionmicroatbuminuria and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study[J],2000(7274).
  • 10Borghi C;Ambrosioni E.Double-blind comparison between zofenopril and Iisinopril in patients with acute myocardial infarction: results of the survival of myocardial infarction long-term evaluation-2 (SMILE-2) study[J],2003(01).

引证文献4

二级引证文献47

世界临床药物
2003年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部